Physician profile
Lori L Shoha
NPI 1588645519
$2,195.72
in general payments reported to CMS, 2019-2025
26 companies · $441 in 2025
The $441 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $138 · 2021: $232 · 2022: $413 · 2023: $557 · 2024: $217 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $431.39 | 2019-2025 | Liletta, Lo Loestrin Fe, Orilissa |
| Sumitomo Pharma America, INC. | $391.58 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $263.73 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $176.11 | 2019-2021 | |
| Therapeuticsmd, INC. | $97.52 | 2019-2022 | |
| Gynesonics, INC. | $96.86 | 2022-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Sage Therapeutics, LLC | $88.85 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $84.01 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $64.21 | 2024-2025 | |
| Myovant Sciences INC. | $61.96 | 2021-2022 | |
| Avion Pharmaceuticals | $52.04 | 2020-2023 | Balcoltra |
| Daiichi Sankyo INC. | $44.68 | 2019-2020 | |
| Aspira Women'S Health INC | $43.28 | 2022 | |
| Coopersurgical, INC. | $42.88 | 2022-2025 | Paragard T 380a |
| Millicent US INC | $37.45 | 2024-2025 | Femlyv, Intrarosa, Femring |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $36.86 | 2022 | |
| Meditrina | $33.07 | 2022 | |
| Tulsa Dental Products LLC | $23.63 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.78 | 2022 | |
| Merck Sharp & Dohme LLC | $21.03 | 2020 | |
| Boston Scientific Corporation | $18.23 | 2025 | Axonics |
| Supernus Pharmaceuticals, INC. | $17.72 | 2025 | Qelbree |
| Allergan, INC. | $16.93 | 2019 | |
| Exact Sciences Corporation | $15.30 | 2024 | Cologuard Collection Kit |
| Duchesnay USA Incorporated | $13.62 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Shoha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.